New trial combines HIV PrEP and STI prevention in one package for young men
NCT ID NCT07658976
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combined approach—offering HIV PrEP (pills or injections) and STI prevention (doxycycline after sex) along with smartphone tools—helps young men at high risk stay protected. About 400 men aged 18-29 who have sex with men will be followed for a year to see if the tools improve PrEP use and reduce infections.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- HIV PrEP (F/TDF, F/TAF, or CAB-LA) and STI PEP (doxycycline)
- What this could lead to
- If successful, this approach could make it easier for young men to stick with HIV prevention and reduce sexually transmitted infections.
- What could go wrong
- This is a Phase 3 trial, but results depend on real-world adherence and may not apply to all populations. The mHealth tools may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 400 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2029
An estimate. End dates often move.
- Lead sponsor
-
A research network
The lead sponsor is a research network or cooperative group.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 29 years
- Sex
-
Male participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Men ages 18 - 29 years 2. Men who are in communities most affected by the HIV epidemic 3. Willing and able to provide informed consent 4. Reports having anal sex with men in the last 6 months 5. Have certain risk factors for HIV acquisition, defined as any of the following in the past 6 months: 1. Any condomless anal sex with a man; not including within a monogamous relationship with an HIV-negative partner or an HIV-positive partner who is virally suppressed 2. Reporting 2 or more male partners, regardless of condom use 3. Reporting gonorrhea, chlamydia, or syphilis diagnosis 4. Any stimulant use (e.g., cocaine, amphetamines) 6. Not on PrEP within the past 3 months due to participant choice 7. Interested in learning more about PrEP or starting PrEP 8. No evidence of HIV infection at Screening and Enrollment, based on the HIV testing algorithm 9. Owns an iOS or Android mobile phone and able to successfully download mobile apps and send and receive text messages 10. Must not share the mobile phone used for their participation in the study 11. Able to read and write Exclusion Criteria: 1. Participated in HPTN 113-01 2. Currently participating in another interventional trial of PrEP agents, or prior enrollment in studies of long-acting PrEP, including HPTN 083 3. Plans to move away from the study area within the next year 4. Currently on doxycycline for STI PEP 5. Has ever used CAB-LA or other long-acting PrEP agent 6. Tetracycline allergy 7. Prior diagnosis of HIV infection 8. Reactive HIV rapid test at Screening or reactive HIV Ag/Ab rapid test at Enrollment, regardless of subsequent HIV test results 9. Any other condition that, in the opinion of the Investigator of Record (IoR)/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives would make the patient unsuitable for the study or unable/unwilling to comply with the study requirements
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
5 sites in 4 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Bronx Prevention Research Center CRS
The Bronx, New York, 10451, United States
-
Fundacion Huesped CRS
Buenos Aires, C1427CEA, Argentina
-
Instituto de Pesquisa Clinicaq Evandro Chagas CRS
Manguinhos, Rio de Janeiro, 221045-900, Brazil
-
San Miguel CRS
Lima, 32-15088, Peru
-
UCLA Vine Street Clinic
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can remote counseling help people with HIV cut back on alcohol?
- Can a Once-Daily HIV pill with food match Twice-Daily dosing during TB treatment?
- Four weeks vs twelve weeks: can a shorter TB prevention course work?
- Can a phone app keep young people with HIV engaged in care?
- Massive Real-World database aims to map how chronic diseases interact
- How do HIV drugs behave when kidneys fail? study measures blood levels